Levamisole Usage as an Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients, Yes or No?

Author Information
Article Notes and Dates
To Cite : Sanadgol H. Levamisole Usage as an Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients, Yes or No?, Nephro-Urol Mon. 2012 ;5(1):673-678. doi: 10.5812/numonthly.3985.
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[DOI][PubMed]
  • 2. Rink L, Gabriel P. Zinc and the immune system. Proceeding-nutrition society of london. 2000;
  • 3. Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005; 20(11): 1641-51[DOI][PubMed]
  • 4. Kong NC, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008; 73(7): 856-62[DOI][PubMed]
  • 5. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50: 1-43[PubMed]
  • 6. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis. 2002; 35(11): 1368-75[DOI][PubMed]
  • 7. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989; 87(3A): 36S-40S[DOI][PubMed]
  • 8. Mahdavimazdeh M, Hosseini-Moghaddam SM, Alavian SM, Yahyazadeh H. Hepatitis B Infection in hemodialysis patients in Tehran province, Iran. Hepat Mon. 2009; 9(3): 206-10
  • 9. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999; 33(2): 356-60[DOI][PubMed]
  • 10. Sali S. HBV Vaccination in Chronic Renal Failure Patients. Hepat Mon. 2006; 6(1): 25-9
  • 11. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002; 78(923): 538-40[DOI][PubMed]
  • 12. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine. 2002; 20(31): 3695-701[DOI][PubMed]
  • 13. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001; 19(15-16): 2055-60[DOI][PubMed]
  • 14. Sanadgol H, Khoshnoodi M, Mashhadi MA, Forghani MS. Effect of adding levamisole on seroconversion response to hepatitis B virus vaccination in hemodialysis patients: a single-center experience. Iran J Kidney Dis. 2011; 5(5): 338-41[PubMed]
  • 15. Slusarczyk Y. who needs vaccination on against hepatitis B Viruses? Vaccine. 2002; 18: 54-5
  • 16. Casciato DA, McAdam LP, Kopple JD, Bluestone R, Goldberg LS, Clements PJ, et al. Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy. Nephron. 1984; 38(1): 9-16[DOI][PubMed]
  • 17. Eardley KS, Jones HE, Osman H, Smith SA. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant. 2002; 17(11): 1982-7[DOI][PubMed]
  • 18. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial. 2000; 13(2): 101-7[DOI][PubMed]
  • 19. Vanholder R, Van Loo A, Dhondt AM, De Smet R, Ringoir S. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant. 1996; 11(4): 593-8[DOI][PubMed]
  • 20. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989; 7(10): 1447-56[PubMed]
  • 21. Aksoy H, Baltaci S, Turkolmez K, Seckiner I, Beduk Y. Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma. Int Urol Nephrol. 2001; 33(3): 457-9[DOI][PubMed]
  • 22. Castro Garzon M, Mubita M, Kachinka L. Levamisole treatment in HIV-infected Zambian children. Lancet. 1992; 340(8827): 1099-100[DOI][PubMed]
  • 23. De Brabander M, Vandebroek J, Wassenaar H, De Cree J, Baisier A, Demoen B, et al. Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. Anticancer Res. 1995; 15(5B): 2271-7[PubMed]
  • 24. Fattovich G, Giustina G, Brollo L, Guido M, Pontisso P, Noventa F, et al. Therapy for chronic hepatitis B with lymphoblastoid interferon‐α and levamisole. Hepatology. 1992; 16(5): 1115-9[DOI][PubMed]
  • 25. Grishchenko SV, Lavrukhina LA, Ketiladze ES, Krylov VF, Ershov FI. [Results of combined therapy using levamisole for patients with influenza complicated by pneumonia]. Vopr Virusol. 1984; 29(2): 175-9[PubMed]
  • 26. Holcombe RF, Li A, Stewart RM. Levamisole and interleukin-2 for advanced malignancy. Biotherapy. 1998; 11(4): 255-8[DOI][PubMed]
  • 27. Katoch K. Immunotherapy of leprosy. Indian J Lepr. 1996; 68(4): 349-61[PubMed]
  • 28. Link KH, Kornmann M, Staib L, Redenbacher M, Kron M, Beger HG. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005; 242(2): 178-87[DOI][PubMed]
  • 29. Molife R, Hancock B. Adjuvant therapy of malignant melanoma. Critic Rev Oncol Hematol. 2002; 44(1): 81-102[DOI][PubMed]
  • 30. Borisova AM, Novikova TA, Glazko AV. [Effect of levamisole on cellular immunity indices in chronic bronchitis and chronic pneumonia patients]. Ter Arkh. 1984; 56(10): 29-31[PubMed]
  • 31. Johnkoski JA, Peterson SM, Doerr RJ, Cohen SA. Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines. Cancer Immunol Immunother. 1996; 43(5): 299-306[DOI][PubMed]
  • 32. Modai D, Weissgarten J, Zolf R, Peller S, Averbukh Z, Kaufman S, et al. Effect of levamisole on chemotaxis of granulocytes from uremic patients. Nephron. 1988; 49(3): 237-9[DOI][PubMed]
  • 33. Demirci F, Bayraktaroglu Z, Karaoglan M, Coskun Y, Karaoglan I, Okan V. Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children. Turk J Gastroenterol. 2005; 16(4): 188-93[PubMed]
  • 34. Luo XL, Wang Y, Tian GS, Fu XX, Wang YY, Wei L, et al. [Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004; 18(3): 284-6[PubMed]
  • 35. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther. 2010; 32(1): 1-10[DOI][PubMed]
  • 36. Fabrizi F, Dixit V, Messa P, Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment Pharmacol Ther. 2010; 32(6): 756-62[DOI][PubMed]
  • 37. Aminzadeh Z, Akhavan H, Gachkar L. Source and response of Antibody to hepatitis B Vaccine in hemodialysis patients. Hepatmon. 2007; 7(1): 33-4
  • 38. Argani H, Akhtarishojaie E. Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines. 2006; 4: 3[DOI][PubMed]
  • 39. Deniz Ayli M, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron. 2000; 84(3): 291-2[DOI][PubMed]
  • 40. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Organs. 2002; 26(6): 492-6[DOI][PubMed]
  • 41. Sali S, Alavian SM, Hajarizadeh B. Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology (Carlton). 2008; 13(5): 376-9[DOI][PubMed]
  • 42. Brodersen HP, Holtkamp W, Larbig D, Beckers B, Thiery J, Lautenschlager J, et al. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study. Nephrol Dial Transplant. 1995; 10(9): 1780[PubMed]
  • 43. Quiroga JA, Castillo I, Porres JC, Casado S, Saez F, Gracia Martinez M, et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology. 1990; 12(4 Pt 1): 661-3[DOI][PubMed]
  • 44. Hassan K, Shternberg L, Alhaj M, Giron R, Reshef R, Barak M, et al. The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren Fail. 2003; 25(3): 471-8[DOI][PubMed]
  • 45. Mauri JM, Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, nonresponder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant. 1997; 12(4): 729-32[DOI][PubMed]
  • 46. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. 1988; 50(2): 133-6[DOI][PubMed]
  • 47. Wang J, Su B, Ding Z, Du X, Wang B. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells. Biochem Biophys Res Commun. 2008; 372(3): 491-6[DOI][PubMed]
  • 48. Perez-Garcia R, Perez-Garcia A, Verbeelen D, Bernstein ED, Villarrubia VG, Alvarez-Mon M. AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int. 2002; 61(5): 1845-52[DOI][PubMed]
  • 49. Renoux G. The general immunopharmacology of levamisole. Drugs. 1980; 20(2): 89-99[DOI][PubMed]
  • 50. Rytel MW. Can therapeutic considerations provide clues to the etiology of aphthous stomatitis and Behcet's syndrome? J Oral Pathol. 1978; 7(6): 372-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check